THARTharimmune, Inc.

Nasdaq hillstreambio.com


$ 0.32 $ -0.06 (-16.52 %)    

Wednesday, 22-May-2024 12:45:54 EDT
QQQ $ 454.82 $ 0.34 (0.07 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -0.58 (-0.26 %)
$ 0.326
$ 0.35
$ 0.00 x 0
$ 0.00 x 0
$ 0.32 - $ 0.36
$ 0.31 - $ 10.87
1,409,752
na
3.83M
$ 0.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-22-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-14-2022 03-31-2022 10-Q
10 04-01-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-tharimmune-thar-shares-are-moving

Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split.

Core News & Articles

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developi...

Core News & Articles

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug...

 tharimmunes-oral-under-the-cheek-candidate-at-par-with-fda-approved-injectable-with-potential-for-chronic-liver-disease

Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential ...

Core News & Articles

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous...

Core News & Articles

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavaila...

Core News & Articles

Planning well underway for Phase 2 of TH104 in primary biliary cholangitis (PBC) patients suffering from moderate-to-severe c...

 perspective-therapeutics-and-3-other-stocks-under-1-insiders-are-buying

The Dow Jones index closed slightly higher on Monday. When insiders purchase or sell shares, it indicates their confidence or c...

Core News & Articles

Phase 1 ex-US trial in chronic liver disease patients in an open-label study showed a 33.3% decrease in 24-hour mean itching in...

 why-hello-group-shares-are-trading-higher-by-around-8-here-are-20-stocks-moving-premarket

Shares of Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter.

 crude-oil-surges-2-tharimmune-shares-plummet

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Tuesday. The Dow tr...

 why-senestech-shares-are-trading-lower-by-around-50-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION